Tags

Type your tag names separated by a space and hit enter

Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model.
Neurosci Lett. 2001 Nov 27; 315(3):149-53.NL

Abstract

Huntington's disease (HD) is a progressive inherited neurodegenerative disorder, for which there is no effective therapy. The CARE-HD study, recently published, evaluated the ability of a combination of coenzyme Q10 (CoQ10) and remacemide hydrochloride (R) to ameliorate symptoms, which might arise from glutamate-mediated excitotoxicity and abnormalities in mitochondrial energy production. In this study, we examined the efficacy of CoQ10/R therapy on ameliorating the motor dysfunction and premature death of HD-N171-82Q transgenic mice. Motor performance, measured on the Rotarod, was specifically but transiently improved beginning 3 weeks after initiating the CoQ10/R therapy. Survival, however was not prolonged. Our findings suggest that further study of CoQ10/R in mouse models is warranted to investigate whether this therapeutic approach can ameliorate the symptoms of HD in early stages of the disease.

Authors+Show Affiliations

Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. schillin@mail.jhmi.eduNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11716985

Citation

Schilling, G, et al. "Coenzyme Q10 and Remacemide Hydrochloride Ameliorate Motor Deficits in a Huntington's Disease Transgenic Mouse Model." Neuroscience Letters, vol. 315, no. 3, 2001, pp. 149-53.
Schilling G, Coonfield ML, Ross CA, et al. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci Lett. 2001;315(3):149-53.
Schilling, G., Coonfield, M. L., Ross, C. A., & Borchelt, D. R. (2001). Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neuroscience Letters, 315(3), 149-53.
Schilling G, et al. Coenzyme Q10 and Remacemide Hydrochloride Ameliorate Motor Deficits in a Huntington's Disease Transgenic Mouse Model. Neurosci Lett. 2001 Nov 27;315(3):149-53. PubMed PMID: 11716985.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. AU - Schilling,G, AU - Coonfield,M L, AU - Ross,C A, AU - Borchelt,D R, PY - 2001/11/22/pubmed PY - 2002/1/24/medline PY - 2001/11/22/entrez SP - 149 EP - 53 JF - Neuroscience letters JO - Neurosci Lett VL - 315 IS - 3 N2 - Huntington's disease (HD) is a progressive inherited neurodegenerative disorder, for which there is no effective therapy. The CARE-HD study, recently published, evaluated the ability of a combination of coenzyme Q10 (CoQ10) and remacemide hydrochloride (R) to ameliorate symptoms, which might arise from glutamate-mediated excitotoxicity and abnormalities in mitochondrial energy production. In this study, we examined the efficacy of CoQ10/R therapy on ameliorating the motor dysfunction and premature death of HD-N171-82Q transgenic mice. Motor performance, measured on the Rotarod, was specifically but transiently improved beginning 3 weeks after initiating the CoQ10/R therapy. Survival, however was not prolonged. Our findings suggest that further study of CoQ10/R in mouse models is warranted to investigate whether this therapeutic approach can ameliorate the symptoms of HD in early stages of the disease. SN - 0304-3940 UR - https://www.unboundmedicine.com/medline/citation/11716985/Coenzyme_Q10_and_remacemide_hydrochloride_ameliorate_motor_deficits_in_a_Huntington's_disease_transgenic_mouse_model_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0304394001023266 DB - PRIME DP - Unbound Medicine ER -